Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).

Authors :: Frascati, Rachel
Early, Amy P.
Reid, Mary E.
Lee, Kelvin
Muhitch, Jason
Mesa, Circe
Luaces, Patricia Lorenzo
Santos-Morales, Orestes
Dozier, Askia
Puzanov, Igor
Fountzilas, Christos
Gandhi, Shipra
Attwood, Kristopher
Hutson, Alan
Johnson, Candace S.
Herrera, Zaima
Saavedra, Danay
Leon, Kalet
Crombet Ramos, Tania
Dy, Grace K.
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p9135-9135, 1p
Publication Year :: 2023

Full Text Access

Tools